Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Three very promising new treatments of NMOSD

MS and NMOSD can present with very similar clinical features. The recent discovery of highly sensitive and specific NMO-specific IgGs that target aquaporin-4 in patients with NMOSD led to NMOSD being considered as a distinct clinical entity. At the AAN 2019 meeting, NMOSD for the first time took centre stage. Results of three promising new therapies were presented: inebilizumab, eculizumab, and satralizumab.

“In the 200 years that we have known about NMO, this year has been the most exciting by far”, said Dr Stacey Clardy (University of Utah, Salt Lake City, USA) in a review session on NMOSD. Her enthusiasm was largely based on 3 monoclonal antibodies in late-stage development for the treatment of NMOSD. Dr Clardy summarised the results of all 3 therapies, that had been presented earlier during the meeting.

Eculizumab

In a randomised, double-blind, time-to-event trial (PREVENT), eculizumab had a significantly lower risk of relapse than placebo among 143 patients with AQP4-IgG–positive NMOSD [1]. The safety profile was similar to that in other indications.

Eculizumab exerts its effect by inhibiting C5 complement activation and subsequent assembly of the membrane attack complex, which is instrumental in effecting astrocytic injury in NMOSD patients. Dr Clardy pointed out that patients were severely ill; they were allowed supportive immunosuppressive therapy. A total of 143 patients were randomised 2:1 to eculizumab (1,200 mg every 2 weeks maintenance) or placebo. As planned, the study was stopped at 23 adjudicated on-trial relapses. Of these, 3 occurred in the eculizumab group and 20 in the placebo group, representing a 94.2% reduction in risk of relapse compared with placebo (HR 0.06; P<0.0001; see Figure). After 48 weeks, 97.9% and 63.2% of patients were relapse-free, respectively. The annualised relapse rate was significantly lower with eculizumab than placebo (0.016 vs 0.350; P<0.0001). The treatment effect was observed regardless of whether or not the patients had received concomitant immunosuppressive agents. Most treatment-related adverse events were mild to moderate.

Figure Analyses of time to first adjudicated relapse

Inebilizumab

In a phase 3, double-masked, placebo-controlled trial (N-MOmentum), inebilizumab was associated with a 77% reduction in risk of relapse in AQP4-IgG seropositive patients (HR 0.227; P<0.0001). The effect on the total population, including AQP4-IgG seronegative patients was similar with a reduction of 73% (HR 0.272; P<0.0001) [2].

Inebilizumab is an anti-CD19 depleting B cell monoclonal antibody. In the inebilizumab study, 231 NMOSD patients (over 90% seropositive for anti-AQP4 antibodies) study were randomised 3:1 to inebilizumab or placebo for 6.5 months. Concurrent treatment with other immunosuppressants was prohibited. After 28 weeks, 89% of actively treated AQP4-IgG seropositive patients were attack-free, versus 58% in the placebo group. On this basis, Prof. Bruce Cree (University of California, San Francisco, USA) explained that further recruitment into the placebo arm was deemed unethical as 43 relapses were observed among the 231 randomised patients. Inebilizumab also demonstrated statistically significant benefits in key secondary endpoints, including reduction in worsening from baseline in Expanded Disability Status Scale (EDSS) scores (P=0.0049); NMOSD-related hospitalisations (P=0.01); and frequency of cumulative total active MRI lesions (P=0.0034). Inebilizumab had a favourable safety and tolerability profile, with an adverse event rate similar to placebo.

Satralizumab

A subgroup analysis of the SAkuraSky study showed that satralizumab is especially effective in reducing relapses in NMO/NMOSD AQP4-antibody-positive patients [3].

Satralizumab is a recycling anti-IL-6 receptor monoclonal antibody. At baseline, 66.3% of patients were AQP4-antibody-positive. In this subgroup, satralizumab showed a 79% risk reduction of relapses compared to placebo (HR 0.21). After 48 and 96 weeks, 91.5% and 91.5% were relapse free with satralizumab, and 59.9% and 53.3% with placebo, respectively. In NMO/NMOSD AQP4-antibody-negative patients, satralizumab reduced the risk of relapse by 34% compared to placebo (HR 0.66). After 48 and 96 weeks, 84.4% and 56.3% were relapse free with satralizumab, and 75.5% and 67.1% with placebo. Satralizumab had a favourable benefit-risk profile.

  1. Pittock SJ, et al. N Engl J Med. 2019 May 3.
  2. Cree B, et al. AAN 2019, Plen02.001.
  3. Yamamura T, et al. AAN 2019, S43.008.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.